Alnylam Pharmaceuticals, Inc. ALNY
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About ALNY
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Alnylam Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company operates primarily within the biopharmaceutical and genetic medicines industries, developing therapies designed to silence disease-causing genes at the messenger RNA level. Alnylam’s core revenue drivers include commercialized RNAi therapies for rare genetic and cardio-metabolic diseases, collaboration revenues from pharmaceutical partnerships, and milestone payments tied to research and development programs.
The company’s commercial portfolio includes products such as ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), and Leqvio under a collaboration arrangement with Novartis. Alnylam primarily serves patients with rare diseases, specialty healthcare providers, and global pharmaceutical partners. Its strategic positioning is based on its early leadership in RNAi therapeutics, extensive intellectual property portfolio, and proprietary delivery technologies, particularly for hepatic targeting. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam evolved from a research-focused RNAi platform company into one of the first firms to achieve broad commercial validation of RNAi-based medicines through multiple regulatory approvals in the United States, Europe, and other international markets.
Business Operations
Alnylam generates revenue through a combination of product sales, licensing agreements, collaboration arrangements, and royalty streams. The company’s operations are organized around the development and commercialization of RNAi therapeutics targeting genetically validated diseases. Commercial operations are concentrated in the United States, Europe, Japan, Latin America, and select international markets through direct infrastructure and strategic partnerships. Key therapeutic focus areas include transthyretin-mediated amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, hypertension, and cardiovascular disease.
The company controls several proprietary technology platforms related to RNAi delivery, including GalNAc-conjugate delivery systems used for liver-targeted therapies. Important collaborations include partnerships with Novartis, Regeneron Pharmaceuticals, and Roche. Alnylam also maintains strategic licensing and co-development arrangements supporting global commercialization and pipeline expansion. Its operations and product development activities are supported by manufacturing relationships and internal research capabilities focused on RNAi chemistry, delivery technologies, and translational medicine.
Strategic Position & Investments
Alnylam’s strategic direction centers on expanding the clinical and commercial applications of RNAi therapeutics while increasing global adoption of existing products. Growth initiatives include advancing late-stage pipeline candidates in cardiovascular and metabolic diseases, broadening geographic commercialization efforts, and investing in next-generation RNAi delivery technologies. The company has emphasized transitioning from ultra-rare disease therapies toward larger population indications, particularly through programs targeting hypertension and cardiovascular risk reduction.
Major strategic investments include continued development of RNAi platform technologies and partnerships designed to extend therapeutic reach beyond hepatic diseases. Alnylam has invested heavily in clinical development programs involving investigational therapies such as zilebesiran and mivelsiran. The company also maintains economic interests through collaborations tied to milestone and royalty structures. Public filings and investor materials indicate ongoing investment in manufacturing scalability, global commercialization infrastructure, and data-generation efforts intended to support long-term market expansion.
Geographic Footprint
Alnylam is headquartered in Cambridge, Massachusetts, with operations and commercial activities spanning North America, Europe, Asia-Pacific, Latin America, and parts of the Middle East. The company maintains a significant presence in the United States and key European pharmaceutical markets, including Germany, France, Italy, Spain, and the United Kingdom. International commercialization is supported through both direct operations and strategic partnerships.
The company’s therapies have received approvals across numerous jurisdictions, including the United States, European Union member states, Japan, Brazil, and Canada. Through collaboration agreements with multinational pharmaceutical companies, Alnylam has expanded its operational influence into additional global markets while leveraging partner distribution networks and regulatory expertise. Its international strategy emphasizes broader access to RNAi therapeutics in both rare disease and large-scale chronic disease categories.
Leadership & Governance
Alnylam was founded by researchers and scientific leaders involved in the early advancement of RNA interference technology, including affiliations with academic institutions and biotechnology innovators. The company’s leadership has consistently emphasized scientific innovation, disciplined clinical execution, and long-term expansion of RNAi therapeutics into mainstream medicine. Corporate governance is overseen by a board of directors and executive leadership team with backgrounds in biotechnology, pharmaceuticals, finance, and global commercialization.
Key executives include:
- Yvonne Greenstreet – Chief Executive Officer
- Tolga Tanguler – Chief Commercial Officer
- Jeff Poulton – Chief Financial Officer
- Pushkal Garg – Chief Medical Officer
- Kevin Fitzgerald – Executive Vice President and Chief Scientific Officer
- Akshay Vaishnaw – President
The company’s leadership strategy, as reflected in public statements, investor presentations, and SEC filings, focuses on building a sustainable multi-product biotechnology enterprise grounded in RNAi innovation, global commercial execution, and continued expansion into broader therapeutic markets.